CY1110733T1 - Κυκλικα παραγωγα ως ρυθμιστες της δραστικοτητας υποδοχεα χημειοκινων - Google Patents
Κυκλικα παραγωγα ως ρυθμιστες της δραστικοτητας υποδοχεα χημειοκινωνInfo
- Publication number
- CY1110733T1 CY1110733T1 CY20101100753T CY101100753T CY1110733T1 CY 1110733 T1 CY1110733 T1 CY 1110733T1 CY 20101100753 T CY20101100753 T CY 20101100753T CY 101100753 T CY101100753 T CY 101100753T CY 1110733 T1 CY1110733 T1 CY 1110733T1
- Authority
- CY
- Cyprus
- Prior art keywords
- regulators
- receptor activity
- atherosclerosis
- chemical receptor
- circulated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
Abstract
Η εφεύρεση αναφέρεται γενικά σε ρυθμιστές της δραστικότητας υποδοχέα χημειοκινών που έχουν μη αναμενόμενο συνδυασμό από επιθυμητές φαρμακολογικές ιδιότητες. Φαρμακολογικές συνθέσεις που περιέχουν τους ως άνω ρυθμιστές και μεθόδους που χρησιμοποιούν τους ως άνω ως παράγοντες αντιμετώπισης και πρόληψης φλεγμονωδών, αλλεργικών, αυτοάνοσων, μεταβολικών, καρκινικών και/ή καρδιαγγειακών ασθενειών, ιδιαίτερα διαβήτη, νόσο του Crohn, αθηροσκλήρωση και σκλήρυνση κατά πλάκας, καθώς και μεθόδους παρασκευής ενώσεων και των ενδιαμέσων τους. Επίσης παρέχονται με το παρόν μεταβολίτες των ενεργών ενώσεων, και επίσης παρέχονται φαρμακευτικές συνθέσεις και η χρήση τους.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83423506P | 2006-07-28 | 2006-07-28 | |
US89602607P | 2007-03-21 | 2007-03-21 | |
US11/782,810 US7687508B2 (en) | 2006-07-28 | 2007-07-25 | Cyclic derivatives as modulators of chemokine receptor activity |
EP07799822A EP2049519B9 (en) | 2006-07-28 | 2007-07-26 | Cyclic derivatives as modulators of chemokine receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110733T1 true CY1110733T1 (el) | 2015-06-10 |
Family
ID=38870321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100753T CY1110733T1 (el) | 2006-07-28 | 2010-08-12 | Κυκλικα παραγωγα ως ρυθμιστες της δραστικοτητας υποδοχεα χημειοκινων |
Country Status (21)
Country | Link |
---|---|
US (1) | US7687508B2 (el) |
EP (1) | EP2049519B9 (el) |
JP (1) | JP5180961B2 (el) |
KR (1) | KR20090051061A (el) |
CN (1) | CN101568532A (el) |
AR (1) | AR062112A1 (el) |
AT (1) | ATE467625T1 (el) |
AU (1) | AU2007279236A1 (el) |
CY (1) | CY1110733T1 (el) |
DE (1) | DE602007006505D1 (el) |
DK (1) | DK2049519T3 (el) |
ES (1) | ES2346100T3 (el) |
HR (1) | HRP20100338T1 (el) |
MX (1) | MX2009000763A (el) |
NO (1) | NO20090205L (el) |
PE (1) | PE20081308A1 (el) |
PL (1) | PL2049519T3 (el) |
PT (1) | PT2049519E (el) |
SI (1) | SI2049519T1 (el) |
TW (1) | TW200813027A (el) |
WO (1) | WO2008014361A2 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629351B2 (en) * | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
MA40320A (fr) * | 2014-07-17 | 2017-05-24 | Santen Pharmaceutical Co Ltd | Agent prophylactique ou thérapeutique pour des troubles du segment postérieur de l'œil |
IL310698A (en) * | 2021-08-13 | 2024-04-01 | Glaxosmithkline Ip Dev Ltd | Cytotoxic targeting chimeras for CCR2-expressing cells |
CA3227835A1 (en) * | 2021-08-13 | 2023-02-16 | Peiling CHEN | Cytotoxicity targeting chimeras |
WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
CN115677728A (zh) * | 2022-11-02 | 2023-02-03 | 成都科岭源医药技术有限公司 | 一种海鞘素类化合物中间体的制备方法 |
WO2024126650A1 (en) | 2022-12-15 | 2024-06-20 | Syngenta Crop Protection Ag | Novel bicyclic-carboxamide compounds useful as pesticides |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6383082A (ja) | 1986-09-26 | 1988-04-13 | Takeda Chem Ind Ltd | テトラヒドロフランカルボン酸誘導体の製造法 |
CA2084800A1 (en) | 1991-12-16 | 1993-06-17 | Joseph P. Vacca | Hiv protease inhibitors with an internal lactam ring |
GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
UA51716C2 (uk) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
US6054579A (en) | 1997-06-26 | 2000-04-25 | Leukosite, Inc. | Synthesis of substituted lactams |
GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
ATE346050T1 (de) | 1998-01-27 | 2006-12-15 | Aventis Pharma Inc | Substituierte oxoazaheterocyclyl faktor xa hemmer |
CA2318601A1 (en) | 1998-01-29 | 1999-08-05 | Aventis Pharmaceuticals Products Inc. | Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound |
US6492553B1 (en) | 1998-01-29 | 2002-12-10 | Aventis Pharamaceuticals Inc. | Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds |
GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
US6541208B1 (en) | 1998-03-17 | 2003-04-01 | University Of Maryland Biotechnology Institute | Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia |
AU7354900A (en) | 1999-09-09 | 2001-04-10 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6620823B2 (en) | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
WO2002050019A2 (en) | 2000-12-20 | 2002-06-27 | Bristol-Myers Squibb Pharma Co. | Diamines as modulators of chemokine receptor activity |
HUP0303652A2 (hu) | 2000-12-20 | 2004-03-01 | Bristol-Myers Squibb Company | Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények |
AU2002249103A1 (en) | 2001-03-29 | 2002-10-15 | Topo Target Aps | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors |
GB0114867D0 (en) | 2001-06-18 | 2001-08-08 | Merck Sharp & Dohme | Therapeutic agents |
DE10135043A1 (de) | 2001-07-11 | 2003-01-30 | Bayer Cropscience Gmbh | Substituierte 3-Heteroaryl(amino- oder oxy)-pyrrolidin-2-one, Verfahren zu deren Herstellung und Verwendung als Herbizide oder als Pflanzenwachstumsregulatoren |
US7087604B2 (en) | 2002-03-08 | 2006-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
AU2003263393A1 (en) | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
US7338975B2 (en) | 2003-02-12 | 2008-03-04 | Bristol-Myers Squibb Co. | Lactams as modulators of chemokine receptor activity |
TW200508224A (en) | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US7317019B2 (en) | 2003-08-21 | 2008-01-08 | Bristol Myers Squibb Co. | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity |
US7863317B2 (en) | 2003-08-21 | 2011-01-04 | Bristol-Myers Squibb Company | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
US20050043392A1 (en) | 2003-08-21 | 2005-02-24 | Carter Percy H. | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
CN101005855A (zh) | 2004-07-30 | 2007-07-25 | 辉瑞产品公司 | 治疗由ccr2介导的疾病或紊乱的方法 |
CA2582225A1 (en) | 2004-09-28 | 2006-04-06 | Mingde Xia | Substituted dipiperdine ccr2 antagonists |
US7671062B2 (en) * | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
US7629351B2 (en) * | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
-
2007
- 2007-07-25 US US11/782,810 patent/US7687508B2/en active Active
- 2007-07-26 PL PL07799822T patent/PL2049519T3/pl unknown
- 2007-07-26 PE PE2007000982A patent/PE20081308A1/es not_active Application Discontinuation
- 2007-07-26 KR KR1020097004296A patent/KR20090051061A/ko not_active Application Discontinuation
- 2007-07-26 ES ES07799822T patent/ES2346100T3/es active Active
- 2007-07-26 AR ARP070103319A patent/AR062112A1/es not_active Application Discontinuation
- 2007-07-26 JP JP2009522953A patent/JP5180961B2/ja not_active Expired - Fee Related
- 2007-07-26 DK DK07799822.7T patent/DK2049519T3/da active
- 2007-07-26 CN CNA200780036308XA patent/CN101568532A/zh active Pending
- 2007-07-26 SI SI200730298T patent/SI2049519T1/sl unknown
- 2007-07-26 AU AU2007279236A patent/AU2007279236A1/en not_active Abandoned
- 2007-07-26 EP EP07799822A patent/EP2049519B9/en active Active
- 2007-07-26 MX MX2009000763A patent/MX2009000763A/es active IP Right Grant
- 2007-07-26 DE DE602007006505T patent/DE602007006505D1/de active Active
- 2007-07-26 AT AT07799822T patent/ATE467625T1/de active
- 2007-07-26 WO PCT/US2007/074378 patent/WO2008014361A2/en active Application Filing
- 2007-07-26 TW TW096127298A patent/TW200813027A/zh unknown
- 2007-07-26 PT PT07799822T patent/PT2049519E/pt unknown
-
2009
- 2009-01-14 NO NO20090205A patent/NO20090205L/no not_active Application Discontinuation
-
2010
- 2010-06-14 HR HR20100338T patent/HRP20100338T1/hr unknown
- 2010-08-12 CY CY20101100753T patent/CY1110733T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE467625T1 (de) | 2010-05-15 |
DK2049519T3 (da) | 2010-09-13 |
US7687508B2 (en) | 2010-03-30 |
EP2049519A2 (en) | 2009-04-22 |
US20080027080A1 (en) | 2008-01-31 |
CN101568532A (zh) | 2009-10-28 |
DE602007006505D1 (de) | 2010-06-24 |
EP2049519B1 (en) | 2010-05-12 |
MX2009000763A (es) | 2009-01-28 |
KR20090051061A (ko) | 2009-05-20 |
WO2008014361A2 (en) | 2008-01-31 |
JP5180961B2 (ja) | 2013-04-10 |
PE20081308A1 (es) | 2008-09-17 |
TW200813027A (en) | 2008-03-16 |
PL2049519T3 (pl) | 2010-10-29 |
HRP20100338T1 (hr) | 2010-07-31 |
NO20090205L (no) | 2009-02-26 |
WO2008014361A3 (en) | 2008-03-06 |
SI2049519T1 (sl) | 2010-08-31 |
JP2009544757A (ja) | 2009-12-17 |
AU2007279236A1 (en) | 2008-01-31 |
AR062112A1 (es) | 2008-10-15 |
PT2049519E (pt) | 2010-08-18 |
EP2049519B9 (en) | 2010-12-29 |
ES2346100T3 (es) | 2010-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110733T1 (el) | Κυκλικα παραγωγα ως ρυθμιστες της δραστικοτητας υποδοχεα χημειοκινων | |
EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
BRPI0512352A (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas | |
BRPI0510665A (pt) | 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
TW200611695A (en) | Pyrrolopyridine derivatives | |
HN2010002774A (es) | DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA | |
EA200800100A1 (ru) | Соединения азаиндазола и способы применения | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
HK1154587A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
BR112012027640A2 (pt) | composto, composição farmacêutica uso de um composto, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 e de tratamento ou prevenção de um distúrbio | |
BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
TW200734323A (en) | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | |
UA109290C2 (uk) | Спільні кристали і солі інгібіторів ccr3 | |
ATE407119T1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
EA200701867A1 (ru) | Хинолиноновые соединения в качестве агонистов рецептора 5-ht | |
MA32062B1 (fr) | Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments | |
AU2011279845A8 (en) | Novel pyrrolidine derived beta 3 adrenergic receptor agonists | |
MA32061B1 (fr) | Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments | |
TW200734335A (en) | Compounds |